Viking Therapeutics Posts Q3 Loss Amid Drug Development
The biotech firm reports a quarterly loss of $1.55 per share while preparing for the future launch of its obesity drug.
Updated on Oct. 29, 2026 in Weight Loss
Live Poll
Do you trust pharmaceutical companies to deliver on long-term drug development timelines?
Viking Therapeutics reported a net loss of $183.2 million for the third quarter of 2026. The company is currently managing expenses as it pushes forward with multiple Phase 3 trials for its weight loss medication, VK2735.
Why it matters
The company is prioritizing heavy research and development spending to bring its obesity treatment to market within two and a half years. Maintaining sufficient capital is critical for Viking to sustain these trials and secure long-term profitability.
Viking Therapeutics reported a quarterly loss of $1.55 per share, supported by $960 million in cash and short-term investments as of September 30, 2026. The company also raised $575 million during the quarter through stock and convertible-note offerings.
The players
Viking Therapeutics
A clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.
Brian Lian
The Chief Executive Officer of Viking Therapeutics who manages the company's long-term strategy for drug development.
The details
Viking is currently conducting four Phase 3 trials for VK2735 while forecasting an average quarterly cash burn of $100 million. The company is also preparing for a 28-day multiple-dose study of its drug candidate VK3019 to begin early next year.
Timeline
September 30, 2026 marked the conclusion of the company's fiscal third quarter.
October 28, 2026 was the date Viking Therapeutics held its latest earnings call.
Early 2027 is when the first patients are expected to join extension studies.
First quarter of 2027 is the planned start for the VK3019 study.
Health Landscape
Viking Therapeutics is utilizing the Phase 3 clinical trial framework to validate its experimental treatments against established medical benchmarks. This work represents a significant milestone in the evolution of weight loss science as the company moves toward commercial readiness.
The company's ongoing clinical trials are a precursor to future treatment options for individuals struggling with weight-related health conditions. Patients should monitor future study results to understand the eventual efficacy and safety profile of the new therapy.
The takeaway
Viking Therapeutics is focusing its financial resources on an aggressive clinical trial timeline to reach the market in the coming years. Investors and patients should continue to track the results of these studies as indicators of the company's long-term commercial success.
What happens next
First patients are expected to enter extension studies in early 2027, followed by the start of a 28-day multiple-dose study of VK3019 in the first quarter of 2027.
Further reading
For more on the current medical developments in this field, visit the Weight Loss section.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Do you trust pharmaceutical companies to deliver on long-term drug development timelines?
